HeartBeam Inc. (NASDAQ: BEAT), a medical technology company specializing in cardiac care, has signed a commercial agreement with Atelier Health, a Beverly Hills-based concierge medical practice, to expand the company's launch footprint into Southern California. The move completes HeartBeam's initial targeted markets, which also include the New York metro area, Dallas, and South Florida, as the company advances commercialization of its cable-free 3D ECG technology for remote cardiac monitoring and preventive cardiology.
HeartBeam's technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG. The platform is intended for portable devices that patients can use outside medical facilities, enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care. The company holds over 20 issued patents related to its technology.
The partnership with Atelier Health, a concierge practice that provides personalized, high-touch care, underscores the growing trend of integrating advanced remote monitoring into premium healthcare services. Concierge medicine, which often involves a membership fee for enhanced access and personalized care, is an ideal setting for HeartBeam's technology, as it aligns with the practice's focus on proactive and preventive health management. Patients of Atelier Health will have access to the cable-free device, allowing for continuous cardiac monitoring without the need for clinic visits.
This expansion is significant for HeartBeam as it demonstrates the company's ability to secure commercial partnerships in key markets, following similar agreements in other regions. The Southern California market, particularly the Beverly Hills area, is known for its affluent population and high demand for premium healthcare services, which could drive adoption of the technology. Additionally, the completion of initial target markets positions HeartBeam to scale its commercialization efforts and potentially expand to other regions.
The implications of this announcement extend beyond HeartBeam's growth. It highlights the increasing role of remote monitoring in cardiology, particularly for arrhythmia detection and preventive care. With FDA clearance for both arrhythmia assessment and 12-lead ECG synthesis, HeartBeam's technology offers a novel approach to cardiac care that could reduce the need for in-person visits and enable earlier intervention. As concierge medicine continues to grow, partnerships like this one could become more common, integrating advanced diagnostics into personalized care models.
For more information on HeartBeam and its technology, visit the company's newsroom at https://ibn.fm/BEAT and its cleared indications for use at https://www.heartbeam.com/indications.
